The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 41 | — | 20.1x | Near average | |
Growth | 1 | — | 5.6% | Below average | |
Quality | 87 | 20.6% | 7.6% | Above average | |
Safety | 26 | 1.2x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Minerva Neurosciences, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Minerva Neurosciences, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Minerva stock is experiencing a stagnation in analyst estimates, with current coverage limited to only one analyst with a price target of $5, which is lower than the current market price ($5.26). There has been no change in the price target over the past 7 and 30-day periods, reflecting a lack of analytical momentum or recent reviews that might re-evaluate the company's financial trajectory.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.